These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37960990)

  • 21. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
    Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
    Long A; Yamamiya I; Valentine M; Machnes Z; Hangai N; Anderson B; Wacheck V; Gao L
    Clin Transl Sci; 2024 Sep; 17(9):e70012. PubMed ID: 39258521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
    Shoaf SE; Bricmont P; Repella Gordon J
    Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
    Sechaud R; Gu H; Rahmanzadeh G; Chiparus O; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):535-547. PubMed ID: 39110203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probe Cocktail to Assess Transporter Function in Sandwich-Cultured Human Hepatocytes.
    Guo C; Brouwer KR; Stewart PW; Mosley C; Brouwer KLR
    J Pharm Pharm Sci; 2019; 22(1):567-575. PubMed ID: 31804919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail.
    Nguyen JT; Tian DD; Tanna RS; Hadi DL; Bansal S; Calamia JC; Arian CM; Shireman LM; Molnár B; Horváth M; Kellogg JJ; Layton ME; White JR; Cech NB; Boyce RD; Unadkat JD; Thummel KE; Paine MF
    Clin Pharmacol Ther; 2021 May; 109(5):1342-1352. PubMed ID: 33174626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
    Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
    Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
    Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
    Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
    Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
    Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
    Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
    J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
    Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
    Lee L; Murase K; Ma J; Thoolen M
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):279-286. PubMed ID: 36478438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.